EUVIMEDOpdag EUVIMED
Systematische ÜbersichtMetaanalyseOpen access · CC BY 4.0

The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005–2025: A Systematic Review and Meta-Analysis

Felix Habarugira iD, Jeanne Batamuriza, Raphael Ndahimana iD, Jules Ndoli Minega iD, Mame Massar Dieng iD, Masceline Jenipher Mutsaka-Makuvaza iD, Tolessa Muleta Daba iD, Youssef Idaghdour iD, Leon Mutesa iD

Pathogens · 2026-02-06 · 15 (2) · 179

DOI: 10.3390/pathogens15020179 ↗

At a glance

Systematische Übersicht in Pathogens, published online on 2026-02-06. Written by Felix Habarugira and 8 co-authors. Institution: Department of Biomedical Laboratory Sciences, School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda, Kigali P.O. B…. Major MEDLINE topics: Plasmodium falciparum, Drug Resistance, Antimalarials, Malaria, Falciparum. Cited 9 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: University of Rwanda, European Union- Team Europe Initiative-MAV+, Access to Quality Vac-cines, Medicines and Health Technologies in Rwanda - Kwigira Project, University of Rwanda, European Union-Team Europe Initiative-MAV+, and Access to Quality Vaccines, Medicines and Health Technologies.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Malaria remains a global health threat, with Plasmodium falciparum causing most deaths, especially in sub-Saharan Africa. Although artemisinin-based therapies reduce the burden, drug-resistant parasites threaten control efforts. Mapping the distribution and evolution of molecular resistance markers is vital for evidence-based strategies. This systematic review mapped the global distribution, pooled prevalence, and temporal trends of key P. falciparum antimalarial resistance markers. Following the PRISMA methodology (PROSPERO: CRD4202511098991), databases (PubMed, Web of Science, Scopus, and Google Scholar) and gray sources were searched (July 2005–July 2025). Data were extracted in Rayyan, assessed via the JBI prevalence tool, and analyzed using Python v3.13 for WHO regional distribution, temporal trends, and treatment outcome trends. Of the 1972 records, 261 studies from 64 countries qualified for inclusion in this review. The pooled prevalence was highest for pfdhfr (85.7%), followed by pfcrt (78.0%), pfdhps (73.7%), pfmdr1 (60.5%), and pfk13 (45.0%). High heterogeneity (I2 > 95%) and rising pfk13 since 2012 highlight emerging artemisinin resistance, while persistent pfdhfr/pfdhps mutations show that ongoing sulfadoxine–pyrimethamine (SP) pressure on P. falciparum drug resistance, decreased parasite clearance, and treatment failure remain widespread and evolving in Africa. Integrating molecular surveillance into national malaria programs is essential to guide treatment modalities and support progress toward malaria elimination.

Subjects

MeSH terms (MEDLINE)

Plasmodium falciparumDrug ResistanceAntimalarialsMalaria, FalciparumHumansArtemisininsProtozoan ProteinsPrevalenceGlobal Health

Author keywords

Plasmodium falciparumartemisinin resistancedrug resistance markerstreatment outcome

Substances

AntimalarialsArtemisininsProtozoan Proteins

Authors and institutions

  • Department of Biomedical Laboratory Sciences, School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda, Kigali P.O. Box 3286, Rwanda.
  • Pathology Department, Research Directorate, University Teaching Hospital of Butare, Huye P.O. Box 254, Rwanda.
  • Department of Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 3286, Rwanda.
  • Program in Biology, Division of Sciences and Mathematics, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates.
  • Department of Medical Biochemistry, Molecular Biology and Genetics, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 3286, Rwanda.
  • Centre for Human Genetics, University of Rwanda, Kigali P.O. Box 4285, Rwanda.

ORCID profiles: Felix Habarugira, Raphael Ndahimana, Jules Ndoli Minega, Mame Massar Dieng, Masceline Jenipher Mutsaka-Makuvaza, Tolessa Muleta Daba, Youssef Idaghdour, Leon Mutesa

Funding

  • University of Rwanda, European Union- Team Europe Initiative-MAV+, Access to Quality Vac-cines, Medicines and Health Technologies in Rwanda - Kwigira Project
  • University of Rwanda, European Union-Team Europe Initiative-MAV+, and Access to Quality Vaccines, Medicines and Health Technologies

Cite

APA

Habarugira, F., Batamuriza, J., Ndahimana, R., Minega, J. N., Dieng, M. M., Mutsaka-Makuvaza, M. J., Daba, T. M., Idaghdour, Y., & Mutesa, L. (2026). The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005–2025: A Systematic Review and Meta-Analysis. Pathogens, 15(2), 179. https://doi.org/10.3390/pathogens15020179

Vancouver

Habarugira F, Batamuriza J, Ndahimana R, Minega JN, Dieng MM, Mutsaka-Makuvaza MJ, et al. The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005–2025: A Systematic Review and Meta-Analysis. Pathogens. 2026;15(2):179. doi:10.3390/pathogens15020179

BibTeX
@article{Habarugira2026,
  author = {Habarugira, Felix and Batamuriza, Jeanne and Ndahimana, Raphael and Minega, Jules Ndoli and Dieng, Mame Massar and Mutsaka-Makuvaza, Masceline Jenipher and Daba, Tolessa Muleta and Idaghdour, Youssef and Mutesa, Leon},
  title = {The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005–2025: A Systematic Review and Meta-Analysis},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {179},
  doi = {10.3390/pathogens15020179}
}
Start for free →